Title |
Safety indicators in patients receiving high-intensity care after hospital admission for acute heart failure: the STRONG-HF trial / |
Authors |
Tomasoni, Daniela ; Davison, Beth ; Adamo, Marianna ; Pagnesi, Mateo ; Mebazaa, Alexandre ; Edwards, Christopher ; Arrigo, Matia ; Barros, Marianela ; Biegus, Jan ; Čelutkienė, Jelena ; Čerlinskaitė-Bajorė, Kamilė ; Chioncel, Ovidu ; Cohen-Solal, Alain ; Damasceno, Albertino ; Diaz, Rafael ; Filippatos, Gerasimos ; Gayat, Etienne ; Kinnoun, Antoine ; Lam, Carolyn S.P ; Novosadova, Maria ; Pang, Peter S ; Ponikowski, Piotr ; Saidu, Hadiza ; Sliwa, Karen ; Takagi, Koji ; Maaten, Jozine M. Ter ; Voors, Adriaan ; Cotter, Gad ; Metra, Marco |
DOI |
10.1016/j.cardfail.2023.09.002 |
Full Text |
|
Is Part of |
Journal of cardiac failure.. Philadelphia : Churchill Livingstone (Elsevier Ltd). 2023, p. [1-13].. ISSN 1071-9164. eISSN 1532-8414 |
Keywords [eng] |
acute heart failure ; guideline-directed medical therapy ; hyperkalemia ; hypotension ; Safety indicators ; STRONG-HF |
Abstract [eng] |
Background: Safety, Tolerability and Efficacy of Rapid Optimization, Helped by NT-proBNP Testing, of Heart Failure Therapies (STRONG-HF) demonstrated the safety and efficacy of rapid up-titration of guideline-directed medical therapy (GDMT) with high-intensity care (HIC) compared with usual care in patients hospitalized for acute heart failure (HF). In the HIC group, the following safety indicators were used to guide up-titration: estimated glomerular filtration rate of 5.0 mmol/L, systolic blood pressure (SBP) of 10% higher than predischarge values. Methods and Results: We examined the impact of protocol-specified safety indicators on achieved dose of GDMT and clinical outcomes. Three hundred thirteen of the 542 patients in the HIC arm (57.7%) met ≥1 safety indicator at any follow-up visit 1–6 weeks after discharge. As compared with those without, patients meeting ≥1 safety indicator had more severe HF symptoms, lower SBP, and higher heart rate at baseline and achieved a lower average percentage of GDMT optimal doses (mean difference vs the HIC arm patients not reaching any safety indicator, –11.0% [95% confidence interval [CI] –13.6 to –8.4%], P < .001). The primary end point of 180-day all-cause death or HF readmission occurred in 15.0% of patients with any safety indicator vs 14.2% of those without (adjusted hazard ratio 0.84, 95% CI 0.48–1.46, P = .540). None of each of the safety indicators, considered alone, was significantly associated with the primary end point, but an SBP of <95 mm Hg was associated with a trend toward increased 180-day all-cause mortality (adjusted hazard ratio 2.68, 95% CI 0.94–7.64, P = .065) and estimated glomerular filtration rate decreased to <30 mL/min/1.73 m2 with more HF readmissions (adjusted hazard ratio 3.60, 95% CI 1.22–10.60, P = .0203). The occurrence of a safety indicator was associated with a smaller 90-day improvement in the EURO-QoL 5-Dimension visual analog scale (adjusted mean difference –3.32 points, 95% CI –5.97 to –0.66, P = .015). Conclusions: Among patients with acute HF enrolled in STRONG-HF in the HIC arm, the occurrence of any safety indicator was associated with the administration of slightly lower GDMT doses and less improvement in quality of life, but with no significant increase in the primary outcome of 180-day HF readmission or death when appropriately addressed according to the study protocol. |
Published |
Philadelphia : Churchill Livingstone (Elsevier Ltd) |
Type |
Journal article |
Language |
English |
Publication date |
2023 |
CC license |
|